Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells.
Zhu Kun-PengChun-Lin ZhangMa Xiao-LongZhang LeiPublished in: Journal of cellular physiology (2018)
Chemoresistance has been an obstacle in the further improvement of 5-year survival rates of osteosarcoma (OS) patients, but the underlying mechanism of chemo-resistance remains unclear. A comprehensive analysis of mRNAs and noncoding RNAs related to OS chemo-resistance could help solve this problem. In the current study, we first identified that fibronectin-1 (FN1), screened by microarray analysis in three paired chemo-resistant and chemo-sensitive OS cell lines, was significantly upregulated in the chemo-resistant OS cell lines and tissues and was related to unfavourable prognosis. Further functional assays revealed that FN1 inhibition greatly increased the sensitivity of OS cells to doxorubicin in vitro and in vivo, whereas FN1 overexpression had the opposite effect. Moreover, mechanistic investigation demonstrated, by a series of assays that included luciferase reporter gene, RNA immunoprecipitation, RNA pull-down and rescue assays, that FN1 expression was regulated by the oncogenic long noncoding RNA (lncRNA) OIP5-AS1 through sponging miR-200b-3p. Thus, these results indicated the role and potential application of the lncRNA OIP5-AS1/miR-200b-3p/FN1 regulatory pathway as a promising target in treatment of OS chemo-resistance.
Keyphrases
- long noncoding rna
- photodynamic therapy
- cancer therapy
- combination therapy
- locally advanced
- induced apoptosis
- drug delivery
- cell cycle arrest
- transcription factor
- high throughput
- ejection fraction
- poor prognosis
- rectal cancer
- gene expression
- oxidative stress
- long non coding rna
- cell death
- cell proliferation
- newly diagnosed
- squamous cell carcinoma
- prognostic factors
- climate change
- risk assessment
- radiation therapy
- binding protein